Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Mar 24, 2025; 16(3): 101098
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.101098
Incorporation of human β-defensin-1 into immunoliposomes to facilitate targeted autophagy therapy of colon carcinoma
Ying Huang, Xi-Ye Wang, Jia-Yue Huang, Zheng-Wei Huang
Ying Huang, Xi-Ye Wang, Jia-Yue Huang, Zheng-Wei Huang, College of Pharmacy, Jinan University, Guangzhou 511443, Guangdong Province, China
Author contributions: Huang Y was responsible for manuscript writing and file sorting; Wang XY and Huang JY were responsible for artwork preparation and manuscript formatting; Huang ZW was responsible for conceptualisation, supervision, manuscript proofreading, fund seeking and submission; all authors have read and agreed to the published version of the manuscript.
Supported by National Natural Science Foundation of China, No. 82104070; and Guangdong Universities Keynote Regions Special Funded Project, No. 2022ZDZX2002.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng-Wei Huang, PhD, Associate Professor, College of Pharmacy, Jinan University, No. 855 East Xingye Dadao, Panyu District, Guangzhou 511443, Guangdong Province, China. huangzhengw@jnu.edu.cn
Received: September 4, 2024
Revised: November 30, 2024
Accepted: December 17, 2024
Published online: March 24, 2025
Processing time: 139 Days and 1.6 Hours
Core Tip

Core Tip: Nanotechnology is a cost-effective strategy for addressing the druggable properties of proteins. We propose an immunoliposome system that improves the stability, bioavailability and targeting properties of human β-defensin-1 (hBD-1), which will support its clinical translation. Our strategy is highly effective and may lead to positive clinical trials and large-scale production. We consider immunoliposomes to be suitable nanovesicles for enhancing the drug properties of hBD-1 and warrant further basic and translational research.